Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

Trial Profile

Characterization of Patients Following Acute Venous Thromboembolism (VTE) and Safety and Effectiveness of Dabigatran Etexilate (DE) in the Treatment and Secondary Prevention of Acute Deep Vein Thrombosis (DVT) and Pulmonary Embolism (PE) in Comparison to Vitamin K Antagonist (VKA) in Routine Clinical Practice - RE-COVERY DVT/PE

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 19 Mar 2018

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Vitamin K antagonists
  • Indications Deep vein thrombosis; Pulmonary embolism
  • Focus Therapeutic Use
  • Acronyms RE-COVERY DVT/PE
  • Sponsors Boehringer Ingelheim
  • Most Recent Events

    • 13 Mar 2018 Status changed from recruiting to active, no longer recruiting.
    • 09 Mar 2018 According to a Boehringer Ingelheim media release, data will be presented at the American College of Cardiology (ACC) 67th Annual Scientific Session.
    • 05 Feb 2018 Planned End Date changed from 31 Dec 2018 to 28 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top